CD8A and colorectal cancer: Similarly, the Immunoscore, which was initially developed in colorectal cancer (106) and is based on CD3+/CD8+ lymphocyte quantification in tumors, predicts disease-free survival and overall survival in colorectal cancer (54, 55) and other cancers (56, 57).